Insulet (NASDAQ:PODD) Lowered to "Peer Perform" Rating by Wolfe Research

Insulet (NASDAQ:PODD - Get Free Report) was downgraded by research analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating in a report released on Tuesday,Briefing.com Automated Import reports.

Several other brokerages also recently issued reports on PODD. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a report on Monday. Stifel Nicolaus raised their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. StockNews.com lowered shares of Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Citigroup lifted their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on shares of Insulet in a report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective on the stock. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $292.06.

Insulet Stock Performance

NASDAQ PODD opened at $259.52 on Tuesday. Insulet has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The stock has a market cap of $18.23 billion, a price-to-earnings ratio of 44.82, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The business has a fifty day moving average of $259.72 and a 200-day moving average of $262.09. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, analysts predict that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.47% of the stock is owned by insiders.

Institutional Investors Weigh In On Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. purchased a new position in shares of Insulet during the 4th quarter worth approximately $36,000. Itau Unibanco Holding S.A. purchased a new position in shares of Insulet during the 4th quarter valued at about $42,000. SRS Capital Advisors Inc. boosted its stake in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares during the period. Golden State Wealth Management LLC boosted its stake in Insulet by 553.1% in the 1st quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after purchasing an additional 177 shares during the period. Finally, Friedenthal Financial bought a new position in Insulet in the 4th quarter worth approximately $57,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.